{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:49:08Z","timestamp":1774129748596,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s41669-023-00471-6","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T07:02:06Z","timestamp":1705734126000},"page":"417-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An Economic Evaluation of a Streamlined Day-Case Atrial Fibrillation Ablation Protocol and Conventional Cryoballoon Ablation versus Antiarrhythmic Drugs in a UK Paroxysmal Atrial Fibrillation Population"],"prefix":"10.1007","volume":"8","author":[{"given":"Joe W. E.","family":"Moss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derick","family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukasz","family":"Grodzicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Palazzolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Mattock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Mealing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxim","family":"Souter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedict","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Bromilow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damian","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McCready","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzahir","family":"Tayebjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewen","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiagarajah","family":"Sasikaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Ismyrloglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prapa","family":"Kanagaratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"key":"471_CR1","unstructured":"National Clinical Guideline Centre. Atrial fibrillation: diagnosis and management. 2021. https:\/\/www.nice.org.uk\/guidance\/ng196."},{"key":"471_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ahj.2019.04.015","volume":"214","author":"I Mann","year":"2019","unstructured":"Mann I, Sasikaran T, Sandler B, Babalis D, Johnson N, Falaschetti E, et al. Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation (AVATAR-AF): design and rationale. Am Heart J. 2019;214:36\u201345. https:\/\/doi.org\/10.1016\/j.ahj.2019.04.015.","journal-title":"Am Heart J"},{"issue":"3","key":"471_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/europace\/euac253","volume":"25","author":"P Kanagaratnam","year":"2023","unstructured":"Kanagaratnam P, McCready J, Tayebjee M, Shepherd E, Sasikaran T, Todd D, et al. Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation: a prospective, randomized, multi-centre, open label trial. EP Europace. 2023;25(3):83\u2013872. https:\/\/doi.org\/10.1093\/europace\/euac253.","journal-title":"EP Europace."},{"key":"471_CR4","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. 2022. https:\/\/www.nice.org.uk\/process\/pmg36."},{"issue":"5","key":"471_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315. https:\/\/doi.org\/10.1016\/j.jval.2012.02.008.","journal-title":"Value Health"},{"issue":"10","key":"471_CR6","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","volume":"14","author":"H Calkins","year":"2017","unstructured":"Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, Aguinaga L, et al. 2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275\u2013444. https:\/\/doi.org\/10.1016\/j.hrthm.2017.05.012.","journal-title":"Heart Rhythm"},{"issue":"6","key":"471_CR7","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.4103\/0028-3886.217947","volume":"65","author":"S Bhaskar","year":"2017","unstructured":"Bhaskar S, Stanwell P, Bivard A, Spratt N, Walker R, Kitsos GH, et al. The influence of initial stroke severity on mortality, overall functional outcome and in-hospital placement at 90 days following acute ischemic stroke: a tertiary hospital stroke register study. Neurol India. 2017;65(6):1252\u20139. https:\/\/doi.org\/10.4103\/0028-3886.217947.","journal-title":"Neurol India"},{"issue":"Suppl 2","key":"471_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12911-018-0625-7","volume":"18","author":"R Zhang","year":"2018","unstructured":"Zhang R, Ma S, Shanahan L, Munroe J, Horn S, Speedie S. Discovering and identifying New York heart association classification from electronic health records. BMC Med Inform Decis Mak. 2018;18(Suppl 2):48. https:\/\/doi.org\/10.1186\/s12911-018-0625-7.","journal-title":"BMC Med Inform Decis Mak"},{"key":"471_CR9","doi-asserted-by":"publisher","unstructured":"Curtis, A. Lesley, Burns, Amanda. Unit Costs of Health & Social Care 2020. Personal Social Services Research Unit; 2020. p. 185. https:\/\/doi.org\/10.22024\/UniKent\/01.02.84818.","DOI":"10.22024\/UniKent\/01.02.84818."},{"key":"471_CR10","unstructured":"All NHS trusts and NHS foundation trusts. National Schedule of NHS Costs Year: 2019-20\u2014HRG Data. NHS; 2021."},{"key":"471_CR11","unstructured":"Kind P, Hardman G, Macran S. UK population norms for EQ-5D. In: Centre for Health Economics, University of York, Working Papers. 1999."},{"issue":"12","key":"471_CR12","doi-asserted-by":"publisher","first-page":"e0226730","DOI":"10.1371\/journal.pone.0226730","volume":"14","author":"F Witassek","year":"2019","unstructured":"Witassek F, Springer A, Adam L, Aeschbacher S, Beer JH, Blum S, et al. Health-related quality of life in patients with atrial fibrillation: the role of symptoms, comorbidities, and the type of atrial fibrillation. PLoS ONE. 2019;14(12):e0226730. https:\/\/doi.org\/10.1371\/journal.pone.0226730.","journal-title":"PLoS ONE"},{"issue":"18","key":"471_CR13","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1212\/WNL.0b013e3182a9f45f","volume":"81","author":"R Luengo-Fernandez","year":"2013","unstructured":"Luengo-Fernandez R, Gray AM, Bull L, Welch S, Cuthbertson F, Rothwell PM. Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study. Neurology. 2013;81(18):1588\u201395. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a9f45f.","journal-title":"Neurology"},{"issue":"12","key":"471_CR14","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/13696998.2020.1854769","volume":"23","author":"J Shore","year":"2020","unstructured":"Shore J, Russell J, Frankenstein L, Candolfi P, Green M. An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK. J Med Econ. 2020;23(12):1425\u201334. https:\/\/doi.org\/10.1080\/13696998.2020.1854769.","journal-title":"J Med Econ"},{"issue":"7","key":"471_CR15","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/europace\/eut395","volume":"16","author":"GJ Wynn","year":"2014","unstructured":"Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014;16(7):965\u201372. https:\/\/doi.org\/10.1093\/europace\/eut395.","journal-title":"Europace"},{"key":"471_CR16","unstructured":"Office for National Statistics. Nomis: Mortality statistics - underlying cause, sex and age. Office for National Statistics; 2020."},{"issue":"8","key":"471_CR17","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1161\/strokeaha.107.511402","volume":"39","author":"G Saposnik","year":"2008","unstructured":"Saposnik G, Cote R, Phillips S, Gubitz G, Bayer N, Minuk J, et al. Stroke outcome in those over 80: a multicenter cohort study across Canada. Stroke. 2008;39(8):2310\u20137. https:\/\/doi.org\/10.1161\/strokeaha.107.511402.","journal-title":"Stroke"},{"issue":"12","key":"471_CR18","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","volume":"33","author":"L Friberg","year":"2012","unstructured":"Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500\u201310. https:\/\/doi.org\/10.1093\/eurheartj\/ehr488.","journal-title":"Eur Heart J"},{"issue":"13","key":"471_CR19","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/circulationaha.116.025941","volume":"135","author":"MN Christiansen","year":"2017","unstructured":"Christiansen MN, K\u00f8ber L, Weeke P, Vasan RS, Jeppesen JL, Smith JG, et al. Age-specific trends in incidence, mortality, and comorbidities of heart failure in Denmark, 1995 to 2012. Circulation. 2017;135(13):1214\u201323. https:\/\/doi.org\/10.1161\/circulationaha.116.025941.","journal-title":"Circulation"},{"key":"471_CR20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/1471-2458-10-637","volume":"10","author":"I Vaartjes","year":"2010","unstructured":"Vaartjes I, Hoes AW, Reitsma JB, de Bruin A, Grobbee DE, Mosterd A, et al. Age- and gender-specific risk of death after first hospitalization for heart failure. BMC Public Health. 2010;10:637. https:\/\/doi.org\/10.1186\/1471-2458-10-637.","journal-title":"BMC Public Health"},{"key":"471_CR21","unstructured":"Joint Formulary Committee. British National Formulary. London: BMJ Group and Pharmaceutical Press. 2022. http:\/\/www.medicinescomplete.com. Accessed 14 Mar 2022."},{"issue":"1","key":"471_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/2396987317746516","volume":"3","author":"XM Xu","year":"2018","unstructured":"Xu XM, Vestesson E, Paley L, Desikan A, Wonderling D, Hoffman A, et al. The economic burden of stroke care in England, Wales and Northern Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke. Eur Stroke J. 2018;3(1):82\u201391. https:\/\/doi.org\/10.1177\/2396987317746516.","journal-title":"Eur Stroke J"},{"key":"471_CR23","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing [program]. Vienna, Austria. 2020. https:\/\/www.R-project.org\/."},{"key":"471_CR24","doi-asserted-by":"publisher","first-page":"664647","DOI":"10.3389\/fcvm.2021.664647","volume":"8","author":"A Saglietto","year":"2021","unstructured":"Saglietto A, Gaita F, De-Ponti R, De-Ferrari GM, Anselmino M. Catheter ablation vs anti-arrhythmic drugs as first-line treatment in symptomatic paroxysmal atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials. Front Cardiovasc Med. 2021;8:664647. https:\/\/doi.org\/10.3389\/fcvm.2021.664647.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"471_CR25","doi-asserted-by":"publisher","first-page":"e007414","DOI":"10.1161\/circep.119.007414","volume":"12","author":"ZUA Asad","year":"2019","unstructured":"Asad ZUA, Yousif A, Khan MS, Al-Khatib SM, Stavrakis S. Catheter ablation versus medical therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Circ Arrhythm Electrophysiol. 2019;12(9):e007414. https:\/\/doi.org\/10.1161\/circep.119.007414.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"4","key":"471_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/fjc.0000000000000654","volume":"73","author":"F Yi","year":"2019","unstructured":"Yi F, Hou W, Zhou C, Yin Y, Lu S, Duan C, et al. Radiofrequency ablation versus antiarrhythmic drug therapy for atrial fibrillation: meta-analysis of safety and efficacy. J Cardiovasc Pharmacol. 2019;73(4):241\u20137. https:\/\/doi.org\/10.1097\/fjc.0000000000000654.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"40","key":"471_CR27","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1093\/eurheartj\/ehab648","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(40):4194\u2013294. https:\/\/doi.org\/10.1093\/eurheartj\/ehab648.","journal-title":"Eur Heart J"},{"issue":"13","key":"471_CR28","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jama.2019.0692","volume":"321","author":"DB Mark","year":"2019","unstructured":"Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1275\u201385. https:\/\/doi.org\/10.1001\/jama.2019.0692.","journal-title":"JAMA"},{"issue":"5","key":"471_CR29","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/europace\/eut380","volume":"16","author":"MR Reynolds","year":"2014","unstructured":"Reynolds MR, Lamotte M, Todd D, Khaykin Y, Eggington S, Tsintzos S, et al. Cost-effectiveness of cryoballoon ablation for the management of paroxysmal atrial fibrillation. Europace. 2014;16(5):652\u20139. https:\/\/doi.org\/10.1093\/europace\/eut380.","journal-title":"Europace"},{"issue":"34","key":"471_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta12340","volume":"12","author":"M Rodgers","year":"2008","unstructured":"Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess. 2008;12(34):1\u2013198. https:\/\/doi.org\/10.3310\/hta12340.","journal-title":"Health Technol Assess"},{"issue":"2","key":"471_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4022\/jafib.195","volume":"2","author":"N Eckard","year":"2009","unstructured":"Eckard N, Davidson T, Walfridsson H, Levin L. Cost-effectiveness of catheter ablation treatment for patients with symptomatic atrial fibrillation. J Atr Fibrill. 2009;2(2):195. https:\/\/doi.org\/10.4022\/jafib.195.","journal-title":"J Atr Fibrill"},{"issue":"3","key":"471_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10840-012-9723-0","volume":"35","author":"N Assasi","year":"2012","unstructured":"Assasi N, Xie F, Blackhouse G, Gaebel K, Robertson D, Hopkins R, et al. Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis. J Interv Card Electrophysiol. 2012;35(3):259\u201375. https:\/\/doi.org\/10.1007\/s10840-012-9723-0.","journal-title":"J Interv Card Electrophysiol"},{"issue":"2","key":"471_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/jce.15317","volume":"33","author":"LWM Leung","year":"2022","unstructured":"Leung LWM, Imhoff RJ, Marshall HJ, Frame D, Mallow PJ, Goldstein L, et al. Cost-effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom. J Cardiovasc Electrophysiol. 2022;33(2):164\u201375. https:\/\/doi.org\/10.1111\/jce.15317.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"471_CR34","unstructured":"National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. Cost-effectiveness analysis J3: Ablation. NICE guideline NG196. Economic analysis report. 2021. https:\/\/www.nice.org.uk\/guidance\/ng196\/evidence\/j3-ablation-health-economics-analysis-pdf-326949243734."},{"issue":"17","key":"471_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jcm10173979","volume":"10","author":"D Sgreccia","year":"2021","unstructured":"Sgreccia D, Manicardi M, Malavasi VL, Vitolo M, Valenti AC, Proietti M, et al. Comparing outcomes in asymptomatic and symptomatic atrial fibrillation: a systematic review and meta-analysis of 81,462 patients. J Clin Med. 2021;10(17):14. https:\/\/doi.org\/10.3390\/jcm10173979.","journal-title":"J Clin Med"},{"issue":"7","key":"471_CR36","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.amjmed.2021.01.017","volume":"134","author":"H Gibbs","year":"2021","unstructured":"Gibbs H, Freedman B, Rosenqvist M, Virdone S, Mahmeed WA, Ambrosio G, et al. Clinical outcomes in asymptomatic and symptomatic atrial fibrillation presentations in GARFIELD-AF: implications for AF screening. Am J Med. 2021;134(7):893-901.e11. https:\/\/doi.org\/10.1016\/j.amjmed.2021.01.017.","journal-title":"Am J Med"},{"key":"471_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijcard.2015.05.011","volume":"191","author":"Q Xiong","year":"2015","unstructured":"Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus symptomatic atrial fibrillation: a systematic review of age\/gender differences and cardiovascular outcomes. Int J Cardiol. 2015;191:172\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.011.","journal-title":"Int J Cardiol"},{"issue":"9","key":"471_CR38","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.hroo.2023.07.007","volume":"4","author":"O Wazni","year":"2023","unstructured":"Wazni O, Moss J, Kuniss M, Andrade J, Chierchia GB, Mealing S, et al. An economic evaluation of first-line cryoballoon ablation vs antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a U.S. Medicare perspective. Heart Rhythm O2. 2023;4(9):528\u201337. https:\/\/doi.org\/10.1016\/j.hroo.2023.07.007.","journal-title":"Heart Rhythm O2"},{"issue":"3","key":"471_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/europace\/euz339","volume":"22","author":"RR De With","year":"2020","unstructured":"De With RR, Marcos EG, Dudink E, Spronk HM, Crijns H, Rienstra M, et al. Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study. Europace. 2020;22(3):352\u201360. https:\/\/doi.org\/10.1093\/europace\/euz339.","journal-title":"Europace"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-023-00471-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T13:07:10Z","timestamp":1714396030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-023-00471-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1007\/s41669-023-00471-6","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"assertion":[{"value":"26 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joe Moss, Lukasz Grodzicki, Beatrice Palazzolo, Richard Mattock, Stuart Mealing, Tom Bromilow, and Damian Lewis were employees of York Health Economics Consortium (YHEC) at the time of this study. YHEC received payment from Medtronic, manufacturer of the Arctic Front Advance Cryoballoon, to conduct the cost-effectiveness analyses and to write the manuscript. Derick Todd and Prapa Kanagaratnam have received personal speaking fees from Medtronic in the past. Maxim Souter, Benedict Brown and Eleni Ismyrloglou were employees of Medtronic at the time of this study. Benedict Brown and Eleni Ismyrloglou also declare holding stock and stock options in Medtronic. James McCready has received personal speaking and consulting fees from Medtronic in the past. Muzahir Tayebjee has previously received a research grant from Medtronic. Ewen Shepherd has previously received honoraria for lectures from Medtronic. Thiagarajah Sasikaran, Clare Coyle and Nicholas A. Johnson have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval was part of the original study but this was a post\u00a0hoc analysis of data therefore no approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent to participate was required as part of the original study but this was a post\u00a0hoc analysis of data therefore no approval was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent for publication was required as part of the original study but this was a post\u00a0hoc analysis of data therefore no approval was required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Medtronic is the manufacturer of the Arctic Front Advance Cryoballoon. Medtronic provided payment to YHEC to conduct the cost-effectiveness analyses and to write the manuscript. The analyses conducted by YHEC were supervised by a Steering Committee made up of two representatives from the AVATAR-AF Steering Committee, two representatives from Imperial College, two representatives from Medtronic and two representatives from YHEC. The AVATAR clinical trial was funded by the British Heart Foundation and an unrestricted research grant from Medtronic Inc. This work was funded by Medtronic, who also provided the medical writing fees.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JM, DT, LG, BP, RM, SM, TB, and DL were responsible for developing the underlying structure of the economic model. JM and BP were responsible for the statistical analysis. JM, DT, SM, MS, BB, CC, NJ, and PK were project steering group members. JM, DT, LG, BP, SM, MS, BB, DL, EI, NJ and PK wrote the main manuscript text. All authors reviewed the manuscript and provided comments, and read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The data underlying this article will be shared upon reasonable request to the primary clinical investigator, Professor Prapa Kanagaratnam (p.kanagaratnam@imperial.ac.uk).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"The code used in this analysis can be made available upon reasonable request to the primary clinical investigator, Professor Prapa Kanagaratnam (p.kanagaratnam@imperial.ac.uk).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}